Science Corporation Raises $400M Series D to Scale PRIMA Retinal Implant
Science Corporation raised a $400M Series D on November 17, 2026, lifting total funding past $900M to expand its CE-marked PRIMA retinal implant in Europe and fund biohybrid neural-interface research.
By Grace Kim
3 min read

What's News
- Science Corporation raised a $400 million Series D announced November 17, 2026, bringing total funding since 2021 above $900 million.
- PRIMA carries 378 light-powered pixels; at 12 months, 80% of study patients showed clinically meaningful visual acuity improvement.
- PRIMA received two FDA Humanitarian Use Device designations on July 22, 2026 but still requires Humanitarian Device Exemption approval for US sale.
- PRIMA is CE marked in the EU and registered for UK supply, but not approved for sale in any other country.
- The biohybrid neural-interface program anchors hundreds of thousands of engineered neurons to a device and remains research-stage.
Science Corporation has raised a $400 million Series D, bringing total funding since its 2021 founding to more than $900 million. The company announced the round on November 17, 2026.
Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech participated, among other investors. Science will use the money to expand availability of its PRIMA retinal implant in Europe, prepare for a US launch, deepen its biohybrid neural-interface program, and grow research, manufacturing and operational infrastructure.
The round backs two things at once: a commercial product with one regulatory market cleared and another pending, and a research-stage neural-interface architecture with no defined therapeutic use yet.
What does PRIMA actually do?
PRIMA is a retinal implant being studied for geographic atrophy caused by dry age-related macular degeneration. Science describes it as the first brain-computer interface CE marked in the European Union to restore form vision — the ability to read letters, numbers and words — for patients blinded by certain types of late-stage macular degeneration. It is registered for supply in the United Kingdom and is not approved or available for sale in any other country.
The hardware is specific. The implant carries 378 light-powered pixels that convert light from the system's glasses into signals stimulating retinal cells. The glasses pair a front-facing camera with an eye-facing projector that shines light precisely onto the implant. The design replicates the function of light-sensitive cells the disease has destroyed.
The clinical numbers come from Science's own product page. At 12 months, 80% of patients in the PRIMA study showed clinically meaningful improvement in visual acuity, and 84% reported reading letters, numbers and words at home with the system. The reported efficacy results include the use of digital zoom and contrast.
Takeaway: the device works well enough in study conditions for Science to sell it in Europe — but the headline figures are company-reported and measured with assistive features in play.
Where does the US approval stand?
On July 22, 2026, Science announced PRIMA had received two FDA Humanitarian Use Device designations. The program expedites review for devices treating rare diseases or conditions, but a designation is not marketing approval. PRIMA must still clear a full Humanitarian Device Exemption review before it can be sold in the US.
The two designations cover distinct patient groups. One covers blindness in both eyes caused by an advanced subset of geographic atrophy, without vision loss from other eye diseases. The other covers vision loss from Stargardt disease, a rare inherited retinal disease.
The US approval process remains underway. That means the Series D cash funds European commercial expansion while the American market — typically the largest for medical devices — stays locked pending regulators.
What is the biohybrid neural-interface program?
The second bet is earlier-stage and more ambitious. Science's biohybrid architecture anchors hundreds of thousands of engineered neurons to a device and uses their projections to form connections with neurons in the brain. MicroLEDs stimulate the embedded neurons, which are modified through optogenetics so light can activate them, while electrodes record their activity.
Science says the architecture can provide orders of magnitude more bandwidth than current devices while avoiding the damage and limitations of inserting wires into the brain. The company lists language and communication, motor control, and learning and reasoning after brain injuries as potential research applications — all still research objectives, not approved uses.
The financing therefore supports two distinct development tracks: commercial expansion of a retinal implant still seeking US approval, and continued development of a neural-interface architecture whose therapeutic uses remain undefined. How quickly the FDA's Humanitarian Device Exemption review moves will likely determine when Science's largest potential market opens.
Source: unite.ai
More from Grace Kim
Show full bio
Market editor covering people, launches and day-to-day practice in entrepreneurship, startups and venture funding at Business Bearings.
2,219 articles